МЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ ПРИ COVID‑19 АССОЦИИРОВАННОМ ТРОМБОЗЕ КАВЕРНОЗНОГО СИНУСА

Э. Н. Билалов, О.И. Орипов, Б. Э. Билалов, К. М. Имомалиева

Передовая Офтальмология · 2023-yil

Annotatsiya

Relevance. The issues of treatment for cavernous sinus thrombosis have not been studied enough due to the rare occurrence of this complication. Purpose of the study. To study the clinical and laboratory efficacy of drug therapy for COVID‑19 associated cavernous sinus thrombosis (CST). Materials and methods. In total, the study included 26 patients who received only conservative treatment. 14 patients (53,8%) out of 26 received conservative treatment according to indications, since they did not have purulent-necroticcomplications of the maxillofacial area and orbit requiring surgical treatment. The remaining 12 patients (46.2%) out of 26 also received conservative treatment despite the presence of indications for surgical treatment associated with purulent-necroticprocesses in the nasal cavity, paranasal sinuses and orbit, but for various reasons did not receive it. The effectiveness of therapy was evaluated after 3 months of observation, taking into account the following criteria: death; the frequency of the transition of the pathological process to a healthy eye; the frequency of development of a purulent-necrotic process, that is, the appearance of indications for surgical treatment; development of frontal encephalitis; development of bleeding on the background of anticoagulant therapy. Results. The results of the study of the effectiveness of conservative therapy showed that in cases of COVID‑19 associated CST, in which severe purulent-necrotic lesions of the maxillofacial area and orbit that require surgical intervention did not develop, rational conservative therapy makes it possible to achieve positive dynamics and prevent the development of complications TKS. At the same time, the following should be considered as the main laboratory indicators of the effectiveness of treatment: achieving an APTT level above 30 seconds; 2 or more fold decrease in the level of D-dimers; 2 or more fold decrease in the level of ferritin; decrease in procalcitonin below 0.25 μg/l.

Maqola ma’lumotlari
MualliflarЭ. Н. Билалов, О.И. Орипов, Б. Э. Билалов, К. М. Имомалиева
JurnalПередовая Офтальмология
Nashr sanasi2023-05-23
Jild3
Son3
Betlar51-55
Tilru
DOI10.57231/j.ao.2023.3.3.010

Передовая Офтальмология jurnalidan boshqa maqolalar

Передовая Офтальмология — barcha maqolalar